Stuart Needleman currently holds the position of Chief Commercial Officer at Piramal Pharma Solutions (PPS), overseeing the company's global business development initiatives. Leading a diverse portfolio of services encompassing drug discovery, clinical development, and commercial supply of both drug substances and products, Mr. Needleman has consistently driven the business development team to achieve record-breaking results throughout his tenure. His expertise lies in steering sustainable growth at attractive margins and cultivating seamless, integrated solutions for drug development and manufacturing.

Mr. Needleman is also responsible for driving profitable growth for the company’s API Generics and Nutrition Solutions Businesses.

In addition to his role as Chief Commercial Officer, Mr. Needleman serves as the Chief Patient Centricity Officer for PPS. In this capacity, his mission is to instill patient-centric behavior throughout the global organization. Ensuring that all employees, from the production floor to the executive suite, comprehend their role in advancing the company's goal of alleviating the burden of disease on patients is central to his responsibilities.

With nearly five decades of experience in the pharmaceutical services industry, Mr. Needleman is a recognized authority in the contract services segment. His leadership roles have spanned global business development, sales and marketing, and operations. Prior to joining Piramal Pharma Solutions (PPS), he held the position of President at Laurus Synthesis, a subsidiary of Laurus Labs, and served as President and Chief Operating Officer at Aptuit, a prominent global contract services company. Over the course of his career, Mr. Needleman has played pivotal roles at Cambrex, Oxford Asymmetry, ChiRex, and Rhodia Pharma Solutions.

Mr. Needleman holds a Bachelor of Science Degree in Chemical Engineering and an MBA from Rensselaer Polytechnic Institute (RPI).